KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Consolidated Net Income (2016 - 2025)

Acadia Pharmaceuticals has reported Consolidated Net Income over the past 16 years, most recently at $273.6 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 90.29% year-over-year to $273.6 million; the TTM value through Dec 2025 reached $391.0 million, up 72.64%, while the annual FY2025 figure was $391.0 million, 72.66% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $273.6 million at Acadia Pharmaceuticals, up from $71.8 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $273.6 million in Q4 2025 and troughed at -$113.1 million in Q1 2022.
  • A 5-year average of $8.6 million and a median of -$6.7 million in 2021 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: plummeted 139.49% in 2023 and later soared 2898.2% in 2024.
  • Year by year, Consolidated Net Income stood at -$43.1 million in 2021, then grew by 3.18% to -$41.7 million in 2022, then surged by 209.65% to $45.8 million in 2023, then skyrocketed by 214.21% to $143.8 million in 2024, then soared by 90.29% to $273.6 million in 2025.
  • Business Quant data shows Consolidated Net Income for ACAD at $273.6 million in Q4 2025, $71.8 million in Q3 2025, and $26.7 million in Q2 2025.